5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The market is segmented by Drug Class (Nonsteroidal anti-inflammatory drugs (NSAIDs), Disease-modifying antirheumatic drugs (DMARDs), Immunosuppressants, Biologic agents, Others), by Route of Administration and by Geography.
Fastest Growing Market:
Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis, which is a condition that develops red patches on the skin with silvery scales. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis. However, the joint problems can sometimes begin before skin patches appear. This condition develops when immune system begins to attack healthy cells and tissue. The abnormal immune response causes inflammation in the joints as well as overproduction of skin cells.
Although it is unclear what triggers the self-harm from immune system, it is likely that both genetic and environmental factors play a major role. One of the major factors that can exacerbate the developemmt of psoiatic artherits in obesity. According to OECD 2017 data, the nearly 37% of the population of United States was classified as obese and the report project the population to increase to 47% by 2030. Hence, as the prevalence of obesity increases, the risk of psoriatic arthritis is expected to increase as well. Other factors like unhealthy lifestyle with indulgence in alcohol and smoking can also be attributed as risk factors for development of psoriatic arthritis. Moreover, development of new therapeutic methods are also expected to drive the growth of this market.
However, side effects from psoriatic arthritis therapeutic drugs and stringent regulations for drugs approval are restraining the growth of this market.
Psoriatic Arthritis therapeutics includes drugs that help relieve pain, reduce inflammation, slow the progression of psoriatic arthritis or directly target parts immune system that trigger inflammation. In the report, a detailed analysis of the psoriatic arthritis therapeutic market is provided. The market is segmented by drug class, route of administration and geography.
|By Drug Class|
|Nonsteroidal anti-inflammatory drugs (NSAIDs)|
|Disease-modifying Antirheumatic Drugs (DMARDs)|
|By Route of Administration|
Report scope can be customized per your requirements. Click here.
NSAIDs are considered the first treatment option for psoriatic arthritis. For people diagnosed with psoriatic arthritis that show only mild symptoms of joint pain and swelling, NSAIDs are usually the first treatment option to consider. NSAIDs are also commonly used as an adjunct treatment in conjunction with biologics or disease-modifying antirheumatic drugs (DMAD) and to treat some severe cases. However, NSAIDs are not advised for people with severe psoriasis because it can cause skin flare ups. However, with advancements in research and technology, safer NSAIDs have been developed with lesser side-effects. This is expected to help the growth of NSAID.
To understand key trends, Download Sample Report
According to 2017 center of disease control and prevention data, the prevalence of obesity has shown an increasing trend among adults in the United States. As per the report, the prevalence of obesity was nearly 30% in 2001-2002 among adults in the US. However, this ratio increased to nearly 40% in 2015-2016. According to OECD, Mexico has one of the highest prevalence of Obesity in the world. As obesity is one of the risk factors of psoriatic arthritis, the high and increasing prevalence is also expected to increase the prevalence of psoriatic arthritis in future.
However, developed countries like US and Canada have structured healthcare system which have fast adoption rate for newer drugs, therapies and technologies. Hence, expenditure on psoriatic arthritis therapeutics is expected to increase with increasing prevalence in future.
To understand geography trends, Download Sample Report.
Majority of the key player involved in research and manufacturing of psoriatic arthritis threrapy drugs are established in developed countries. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness. This has also helped the market growth.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Obesity
4.2.2 Adoption of Unhealthy Lifestyle
4.2.3 Emergence of new Therapeutics with Advanced Research
4.3 Market Restraints
4.3.1 Stringent Regulations for Drug Approval
4.3.2 Side Effects from Therapeutic drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Nonsteroidal anti-inflammatory drugs (NSAIDs)
5.1.2 Disease-modifying Antirheumatic Drugs (DMARDs)
5.1.4 Biologic agents
5.2 By Route of Administration
5.3.1 North America
220.127.116.11 Rest of Europe
5.3.3 Asia Pacific
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East and Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.2 Eisai Inc
6.1.3 UCB Biosciences Inc
6.1.5 Otsuka Pharmaceutical
6.1.6 Sumitomo Dainippon Pharma Co
6.1.7 Johnson & Johnson
6.1.8 Celgene Corporation
6.1.9 AbbVie Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments